Secures $11M in Highly Dilutive Private Placement, Addresses Nasdaq Listing, Plans Reverse Split

summarizeSummary

Aspire Biopharma closed the initial tranche of a highly dilutive $21 million private placement, raising $11 million to meet Nasdaq listing requirements, with plans for a significant reverse stock split and authorized share increase.

check_boxKey Events

• Initial Closing of Private Placement

  The company completed the initial closing of a private placement on February 6, 2026, issuing 13,750 shares of Series A Convertible Preferred Stock for gross proceeds of $11 million, including the conversion of $943,801 in existing debt. A second closing for up to an additional $10 million is contingent on shareholder approval and registration statement effectiveness.

• Highly Dilutive Conversion Terms

  The Series A Convertible Preferred Stock is convertible into common stock at 80% of the lowest closing price over the five trading days prior to conversion, subject to a floor price of 20% of the Nasdaq Minimum Price. This structure is highly unfavorable to existing common shareholders.

• Addresses Nasdaq Listing Requirements

  The capital raise is intended to enable the company to regain compliance with Nasdaq's stockholders' equity listing requirements, which is a critical step for continued listing.

• Proposed Reverse Stock Split and Authorized Share Increase

  The company will seek shareholder approval for a reverse stock split at a range of 1-for-5 to 1-for-500 shares, and an amendment to increase its authorized shares, typically indicative of efforts to manage share price and facilitate future capital raises.

auto_awesomeAnalysis

Aspire Biopharma Holdings, Inc. announced the initial closing of a private placement, raising $11 million through the issuance of Series A Convertible Preferred Stock. This capital raise is critical for the company to meet Nasdaq's minimum stockholders' equity requirement, providing a near-term survival pathway. However, the terms of the preferred stock are highly dilutive, allowing conversion at 80% of the lowest closing price over five trading days, with a very low floor price. This structure, often seen in distressed financings, poses a significant risk of substantial dilution for existing shareholders. The company also plans to seek shareholder approval for a reverse stock split (ranging from 1-for-5 to 1-for-500) and an increase in authorized shares, which are typically negative signals indicating efforts to maintain listing compliance and facilitate further capital raises. The filing follows a previous 8-K on February 6, 2026, which likely detailed the Certificate of Designation for the Series A Preferred Stock, and this filing provides the crucial details of the initial closing and its implications. Additionally, a director resigned, and a new director was appointed, fulfilling an investor right related to the financing.